HeartSciences posts quarterly results update for Oct. 31, 2025

HeartSciences Inc. disclosed that it issued a press release providing financial and operating results for the quarter ended October 31, 2025, along with other business updates.

Rhea-AI Filing Summary

HeartSciences Inc. disclosed that it issued a press release providing financial and operating results for the quarter ended October 31, 2025, along with other business updates. The press release is attached as Exhibit 99.1 and incorporated by reference into the report.

The company states that the information in Item 2.02 and Exhibit 99.1 is being treated as “furnished,” not “filed,” under the Exchange Act, and is not subject to the liabilities of Section 18 or automatically incorporated into other Securities Act or Exchange Act filings except by specific reference. The report is signed by Andrew Simpson, President, Chief Executive Officer and Chairman of the Board.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did HeartSciences Inc. (HSCS) disclose in this report?

HeartSciences Inc. disclosed that it issued a press release with financial and operating results for the quarter ended October 31, 2025, plus other business updates, and attached it as Exhibit 99.1.

Which period does the latest HeartSciences (HSCS) financial update cover?

The update covers HeartSciences’ financial and operating results for the quarter ended October 31, 2025.

How is the HeartSciences press release treated under U.S. securities laws?

The company states that the information in Item 2.02 and Exhibit 99.1 is being “furnished,” not “filed,” under the Exchange Act and is not subject to the liabilities of Section 18 or automatically incorporated into other Securities Act or Exchange Act filings except by specific reference.

Where can investors find the detailed HeartSciences (HSCS) financial results?

Detailed results are contained in the press release that HeartSciences attached as Exhibit 99.1, described as “Press Release dated October 31, 2025.”

Who signed the HeartSciences Inc. report covering the October 31, 2025 quarter?

The report was signed by Andrew Simpson, who serves as President, Chief Executive Officer and Chairman of the Board of Directors of HeartSciences Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/15/2025 - 04:17 PM EST Learn about SEC filing dates

0001468492false00014684922025-12-152025-12-150001468492us-gaap:WarrantMember2025-12-152025-12-150001468492us-gaap:CommonStockMember2025-12-152025-12-15

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 15, 2025

HEARTSCIENCES INC.

(Exact name of Registrant as Specified in Its Charter)

Texas			001-41422	26-1344466
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
550 Reserve Street, Suite 360
Southlake, Texas				76092
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 682 237-7781

n/a

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		HSCS		The Nasdaq Stock Market LLC
Warrants		HSCSW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On December 15, 2025, HeartSciences Inc. (the “Company”) issued a press release providing information regarding the Company’s financial and operating results for the quarter ended October 31, 2025, and other business updates. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated by reference herein.

The information contained in Item 2.02 of this Current Report and Exhibit 99.1 to this Current Report shall not be deemed to be “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
99.1*		Press Release dated October 31, 2025
Exhibit 104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			HEARTSCIENCES INC.
Date:	December 15, 2025	By:	/s/ Andrew Simpson
			Andrew Simpson President, Chief Executive Officer and Chairman of the Board of Directors